Plain-English translation of NCT06941129 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called universal allogeneic anti-CD19/BCMA CAR T-cell therapy for people with autoimmune diseases that have not improved with standard medications. CAR T-cell therapy works by using specially engineered immune cells to target and calm down the B cells that are causing your immune system to attack your own body. You would receive a single infusion of this medication after preparing your body with chemotherapy drugs.
Standard treatments for severe autoimmune diseases don't work for everyone—some people's diseases keep coming back or never improve no matter what medications they try. This trial exists to see if this new type of immune cell therapy might help people whose diseases have become resistant to conventional treatment.
You likely qualify if…
You likely don't qualify if…
You would first receive chemotherapy drugs (fludarabine and cyclophosphamide) to prepare your body, then receive a single intravenous infusion of the CAR T cells. After that, you would return for visits at regular intervals—with important check-ins at 12 and 24 weeks after your infusion—so doctors can monitor how you respond and watch for any side effects. The study involves blood tests and clinical assessments to see if your autoimmune disease improves.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Shanghai Xiniao Biotech Co., Ltd.
Enrollment target
~12 participants
Started
February 2025
Primary completion
February 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ying Wang, PhD
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.